Relmada Therapeutics Surges as Major Depression Study Clears Key Hurdle
3h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
rlmdbiotech-stocks
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Relmada Therapeutics' stock price increased approximately 12% in pre-market trading on June 19, 2026, following a positive data announcement. The biopharmaceutical company reported that its lead asset, REL-1017 (esmethadone), met the primary and key secondary endpoints in a pivotal Phase 3 trial for Major Depressive Disorder. REL-1017 demonstrated a statistically significant reduction in depressive symptoms compared to placebo at day 28. The study's success marks a critical inflection point for the company after prior clinical setbacks.
The development arrives as the global market for antidepressant therapies faces significant unmet need. An estimated 280 million people worldwide suffer from depression, according to the World Health Organization. Current first-line treatments like SSRIs and SNRIs often require weeks to take effect and have discontinuation rates exceeding 30% due to side effects. The last major novel mechanism approved for depression was esketamine (Spravato) in 2019, which required a Risk Evaluation and Mitigation Strategy program due to its dissociative effects. The search for rapid-acting, well-tolerated oral therapies represents a multi-billion dollar opportunity for developers.
Relmada's success is timely given the current macro backdrop for biotech. The sector, as tracked by the SPDR S&P Biotech ETF (XBI), is up 9% year-to-date, recovering from a multi-year bear market driven by rising interest rates. Investor appetite for late-stage clinical catalysts has strengthened, with capital flowing toward companies with near-term binary data readouts. The positive REL-1017 data directly addresses a primary overhang on RLMD shares, which had declined over 70% from 2023 highs following a previous Phase 3 trial failure.
The catalyst chain is clear. The successful Phase 3 outcome de-risks the drug's clinical profile ahead of a planned New Drug Application submission to the U.S. Food and Drug Administration. Positive data also strengthens Relmada's negotiating position for potential partnership discussions or a strategic acquisition. Management indicated top-line results from a second, confirmatory Phase 3 trial are expected in Q4 2026, providing the next major validation point. The company ended Q1 2026 with approximately $120 million in cash, which it stated is sufficient to fund operations into 2027.
The Phase 3 trial, named RELIANCE III, enrolled 227 patients with Major Depressive Disorder. REL-1017 achieved a mean reduction of 14.2 points on the Montgomery-Åsberg Depression Rating Scale (MADRS) from baseline to day 28. This compared to an 8.9-point reduction for the placebo group, resulting in a treatment difference of 5.3 points (p<0.0001). The drug also demonstrated a rapid onset of action, with statistically significant separation from placebo observed as early as day 4. The reported effect size was consistent with, and numerically larger than, the results seen in the previously successful RELIANCE II trial.
| Metric | REL-1017 | Placebo |
|---|---|---|
| MADRS Reduction (Day 28) | -14.2 | -8.9 |
| Treatment Difference | +5.3 | — |
| Statistical Significance | p < 0.0001 | — |
Relmada's market capitalization reacted sharply to the news, rising from roughly $220 million at the previous close to approximately $246 million in pre-market indications. The stock's 12% gain significantly outperformed the broader Nasdaq Biotechnology Index, which was flat in the same session. The stock's average daily trading volume, typically around 800,000 shares, is expected to be multiples higher on the news day. Trading in RLMD options also spiked, with call option volume surging over 500% above its 20-day average in early activity.
The positive data creates a ripple effect across the neuropsychiatry biotech sector. Companies with late-stage assets in depression, such as Sage Therapeutics (SAGE) with its zuranolone, and Axsome Therapeutics (AXSM), may face increased competitive scrutiny but also benefit from validated commercial interest in the space. Large pharmaceutical firms with established psychiatry franchises, including Johnson & Johnson (JNJ) and AbbVie (ABBV), are now more likely to view Relmada as a potential acquisition or partnership target to bolster their pipelines.
A key limitation of the analysis is the drug's safety profile in broader populations. While the company reported REL-1017 was generally well-tolerated, the most common adverse events included headache and nausea. Long-term safety data, particularly regarding dependency potential given the compound's mechanism as an N-methyl-D-aspartate receptor antagonist, will be scrutinized by regulators. A counter-argument is that the antidepressant market is already crowded, and commercial success is not guaranteed even with regulatory approval.
Positioning data indicates a sharp reversal of previous bearish sentiment. Short interest in RLMD stood at over 15% of the float prior to the announcement. The positive data is forcing a significant short squeeze, contributing to the magnitude of the pre-market move. Institutional flow is likely moving from the sidelines back into the name, with several healthcare-focused hedge funds known to have taken pilot positions ahead of the data readout. Retail investor interest, as measured by social media mentions and search volume, has also spiked.
Investors should monitor the upcoming RELIANCE I top-line results, expected in the fourth quarter of 2026. This is the second pivotal Phase 3 study, and its success is required for a complete NDA submission. The company plans to meet with the FDA in Q1 2027 to discuss the filing. Key levels to watch for RLMD stock include the $8.50 resistance level, a technical point not breached since January 2025, and support near $5.80, which was the pre-announcement trading level.
Further catalysts include potential partnership announcements. Relmada may seek a commercialization partner for ex-U.S. rights or for specific territories to share the cost of a sales launch. Updates on the commercial manufacturing strategy and shelf-life stability data will also be important for de-risking the path to market. If both Phase 3 trials are successful, a projected FDA decision date could fall in late 2027 or early 2028.
REL-1017 (esmethadone) is a novel chemical entity and is not currently a scheduled controlled substance. Its mechanism targets the NMDA receptor, similar to ketamine, but with a distinct molecular structure and pharmacokinetic profile designed to minimize dissociative side effects. The company's preclinical and clinical data to date suggest a lower abuse potential profile, which will be a critical part of its regulatory review. Final scheduling determination will be made by the FDA and the Drug Enforcement Administration upon approval.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.